文献速递肝病消化道肿瘤与早癌

骨桥蛋白诱导的集落刺激因子-1信号通路破坏肿瘤相关巨噬细胞转运使肝细胞癌对抗PD-L1阻断敏感

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
PubMed 文献 · Gut · 2019-03-22

该研究在化学诱导的野生型与骨桥蛋白敲除小鼠肝癌模型中分析肿瘤浸润免疫细胞与炎症免疫特征,并通过体外共培养及过表达骨桥蛋白的皮下或原位肝癌小鼠模型评估抗PD-L1与CSF1/CSF1R抑制的疗效。结果显示骨桥蛋白经CSF1-CSF1R通路促进巨噬细胞趋化迁移、替代活化及肝癌PD-L1表达,联合抗PD-L1与CSF1R抑制在骨桥蛋白高表达荷瘤小鼠中产生抗肿瘤活性并延长生存。

要点

  • 骨桥蛋白敲除小鼠肿瘤组织中肿瘤相关巨噬细胞数量、M2标志物及PD-L1表达显著降低,Th1细胞因子水平上调。
  • 肝癌患者肿瘤组织中骨桥蛋白与PD-L1表达、骨桥蛋白与肿瘤相关巨噬细胞浸润呈正相关。
  • 联合抗PD-L1与CSF1R抑制在骨桥蛋白高表达荷瘤小鼠中产生抗肿瘤活性并延长生存。

核心结论

  • 骨桥蛋白/CSF1/CSF1R轴在肝细胞癌微环境的免疫抑制中起关键作用,阻断CSF1/CSF1R可阻止肿瘤相关巨噬细胞转运,从而增强免疫检查点抑制剂治疗肝细胞癌的疗效。

研究设计与样本

  • 研究分析化学诱导的野生型与骨桥蛋白敲除小鼠肝癌模型中肿瘤浸润免疫细胞数量及炎症免疫特征。
  • 体外细胞共培养研究骨桥蛋白、集落刺激因子-1(CSF1)及CSF1受体(CSF1R)介导的肿瘤相关巨噬细胞与肝细胞癌细胞间交互作用。
  • 在过表达骨桥蛋白的皮下或原位肝癌小鼠模型中评估抗PD-L1与CSF1/CSF1R抑制的体内疗效。

主要发现

  • 与对照相比,骨桥蛋白敲除小鼠肿瘤组织中肿瘤相关巨噬细胞数量、M2巨噬细胞标志物及PD-L1表达水平显著降低,Th1细胞产生的细胞因子水平上调。
  • 肝细胞癌患者肿瘤组织中骨桥蛋白与PD-L1表达呈正相关,骨桥蛋白表达与肿瘤相关巨噬细胞浸润呈正相关。
  • 骨桥蛋白通过激活巨噬细胞中CSF1-CSF1R通路促进趋化迁移、巨噬细胞替代活化,并促进肝细胞癌细胞PD-L1表达。
  • 联合抗PD-L1与CSF1R抑制在骨桥蛋白高表达荷瘤小鼠中产生强效抗肿瘤活性并延长生存。
  • 组织学、流式细胞术及ELISA显示多个肝细胞癌小鼠模型中CD8+ T细胞浸润增加、肿瘤相关巨噬细胞减少、Th1/Th2细胞因子平衡增强。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the tumour microenvironment, critical drivers of immune escape include the oncogenic activity of the tumour cell-intrinsic osteopontin (OPN), the expression of programmed death ligand 1 (PD-L1) and the expansion of tumour-associated macrophages (TAMs). We investigated the feasibility of targeting these pathways as a therapeutic option in hepatocellular carcinoma (HCC) mouse models. DESIGN: We analysed the number of tumour-infiltrating immune cells and the inflammatory immune profiles in chemically induced liver tumour isolated from wild-type and OPNknockout (KO) mice. In vitro cell cocultures were further conducted to investigate the crosstalk between TAMs and HCC cells mediated by OPN, colony stimulating factor-1 (CSF1) and CSF1 receptor (CSF1R). The in vivo efficacy of anti-PD-L1 and CSF1/CSF1R inhibition was evaluated in OPN overexpressing subcutaneous or orthotopic mouse model of HCC. RESULTS: The numbers of TAMs, as well as the expression levels of M2 macrophage markers and PD-L1 were significantly decreased, but the levels of cytokines produced by T-helper 1 (Th1) cells were upregulated in tumour tissues from OPN KO mice compared with that from the controls. In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumour tissues from patients with HCC. We further demonstrated that OPN facilitates chemotactic migration, and alternative activation of macrophages, and promotes the PD-L1 expression in HCC via activation of the CSF1-CSF1R pathway in macrophages. Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged survival of OPNhigh tumour-bearing mice. Histological, flow cytometric and ELISA revealed increased CD8+ T cell infiltration, reduced TAMs and enhanced Th1/Th2 cytokine balance in multiple mouse models of HCC. CONCLUSIONS: OPN/CSF1/CSF1R axis plays a critical role in the immunosuppressive nature of the HCC microenvironment. Blocking CSF1/CSF1R prevents TAM trafficking and thereby enhances the efficacy of immune checkpoint inhibitors for the treatment of HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019. PMID: 30902885. doi:10.1136/gutjnl-2019-318419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。